An interventional study of Lavender in Primary Hypertension, sponsored by Ardahan University. Recruiting at 1 site in Turkey (Türkiye). Per ClinicalTrials.gov, last updated 2025-09-25.
Sponsored by Ardahan University · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies in Essential Hypertension with a site in Turkey — 6 open to participants now, 6 under way, none of them phase 3. Essential Hypertension · Turkey.
Among the 21 studies in Essential Hypertension with a site in Turkey, this one is the 16th largest by planned enrollment of the 19 interventional ones that give a count, is one of 2 that started in 2025, is one of 11 with no phase, and was the 16th registered.
481 studies on the registry are indexed under Essential Hypertension; 75 are open to participants now.
Browse Essential Hypertension studies →6 of the 21 studies in Essential Hypertension with a site in Turkey are open now. Recruiting first, the newest first:
Abant Izzet Baysal University · Sites in Turkey
Ages 18–65
Yelda Kasımoğlu · Sites in Turkey
Ages 10–18 · Healthy volunteers
Inonu University · Sites in Turkey
Ages 30–65
Eskisehir Osmangazi University · Sites in Turkey
Ages 25–59 · Healthy volunteers
TC Erciyes University · Sites in Turkey
Ages 18 mo–65 mo
A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →
Of the 43 Essential Hypertension studies recruiting now, 15 (35%) set no upper age limit and 20 (47%) stop at 75 or younger; 4 take children under 18; 11 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 2 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 50 is below the median of 144 across 408 interventional studies indexed under Essential Hypertension.
Median enrollment 130 across the 19 interventional studies, 93 across the 2 observational. Of the 14 that completed or were terminated, 7 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 21 have an industry lead sponsor. The 10 most frequent:
Ardahan University is the lead sponsor of 12 studies on the registry; 5 are open to participants now.
Ardahan University has 1 study filed under Essential Hypertension — fewer than ten, so there is no comparison to draw.
1 of the studies in Essential Hypertension with a site in Turkey that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07577973Abant Izzet Baysal UniversityThe Effect of Self-Acupressure on Blood Pressure, Stress, and Well-Being Levels in Individuals With Hypertension | 2026-12-01 |
Add it to your calendar (.ics) → With an account.
Among the 21 studies in Essential Hypertension with a site in Turkey, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study aims to determine the effects of lavender oil inhalation on anxiety, sleep quality, and blood pressure in patients with primary hypertension. The study is designed as a double-blind randomized controlled trial. The study population consists of patients presenting to the Cardiology Outpatient Clinic of Ardahan State Hospital. Participants are randomly assigned to an experimental group, which will receive a total of 12 lavender oil inhalations three times a week for one month, or to a control group, which will continue routine treatment and care. Data will be collected using the Hypertension Diagnostic Form, Beck Anxiety Inventory, and Pittsburgh Sleep Quality Index. Statistical analyses will be conducted to compare outcomes between the experimental and control groups.
This study aims to evaluate the effects of lavender oil inhalation on anxiety, sleep quality, and blood pressure in patients with primary hypertension. It is designed as a double-blind randomized controlled trial. Patients presenting to the Cardiology Outpatient Clinic of Ardahan State Hospital will be recruited for the study. Participants will be randomly assigned to an experimental group, which will receive 12 lavender oil inhalations three times a week for one month, or to a control group, which will continue routine care. Data will be collected using the Hypertension Diagnostic Form, Beck Anxiety Inventory, and Pittsburgh Sleep Quality Index. The study will assess whether lavender oil inhalation affects anxiety, sleep quality, and blood pressure in this population. Statistical analyses will be conducted to compare outcomes between the experimental and control groups.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participants receive lavender oil inhalation three times per week for one month (total of 12 sessions) in addition to routine care for primary hypertension. Anxiety, sleep quality, and blood pressure are assessed before and after the intervention.
Other: Lavender
Participants in the control group continue their routine care and treatment for primary hypertension without receiving lavender oil inhalation. Anxiety, sleep quality, and blood pressure are assessed before and after the study period.
Participants receive lavender oil inhalation three times per week for one month (total of 12 sessions) using a standardized diffuser. This intervention is provided in addition to routine care for primary hypertension. Outcomes measured include anxiety, sleep quality, and blood pressure before and after the intervention.
Anxiety
Measured using the Beck Anxiety Inventory (BAI) at baseline, week 2, and week 4. Higher scores indicate higher anxiety.
Time frame: Baseline, Week 2, Week 4
Blood Pressure
Measured using the Hypertension Diagnostic Form at baseline, week 2, and week 4. Includes systolic and diastolic measurements.
Time frame: Baseline, Week 2, Week 4
Sleep quality
Measured using the Pittsburgh Sleep Quality Index (PSQI) at baseline, week 2, and week 4. Higher scores indicate poorer sleep quality
Time frame: Baseline, Week 2, Week 4
Plan to share: No — Individual participant data will not be shared due to confidentiality and privacy concerns of study participants.
No publications or documents are linked to this record.
Started Jul 2025 (actual). Primary completion is estimated for Oct 2025, 3 months after the start.
Of 70 non-industry interventional studies with no phase under Essential Hypertension, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 47. This study's planned 3 months is below that.
Counting every sponsor, half of 80 studies reached it within 20 months; a quarter within 8 and three quarters within 48.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Ardahan University